| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2caaba601fd6460c7b37706d920d42e2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2014-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c6f93a2cba5bdd7cb0b91a2423a07b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42a79c58d78cae40af3545ca0eacfe11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7ea058b9ee10f75444bf1990ed8c376
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c590e2b18215c11179b0f8e0639a401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86afd6e57143fd16ed5c402f6737c3d9 |
| publicationDate |
2016-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AR-097973-A1 |
| titleOfInvention |
PHARMACEUTICAL FORMULATION INCLUDING GONADOTROPINE LIBERATING HORMONE (GnRH), A GnRH AGONIST OR A GnRH ANTAGONIST AND TREATMENT METHOD |
| abstract |
Claim 1: A pharmaceutical formulation comprising a solid matrix of one or more biodegradable polymers, the solid matrix that includes a pharmaceutically active principle or one of its pharmaceutically acceptable salts distributed homogeneously or substantially homogeneously within matrix; wherein the pharmaceutically active principle is gonadotropin-releasing hormone (GnRH), a GnRH agonist or a GnRH antagonist. Claim 2: A pharmaceutical formulation according to claim 1 wherein the pharmaceutically active principle is degarelix. Claim 7: A pharmaceutical formulation according to any of the preceding claims wherein the (or each) biodegradable polymer is a copolymer of lactic and glycolic acid (PLGA). |
| priorityDate |
2013-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |